CL2022000147A1 - Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. - Google Patents
Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.Info
- Publication number
- CL2022000147A1 CL2022000147A1 CL2022000147A CL2022000147A CL2022000147A1 CL 2022000147 A1 CL2022000147 A1 CL 2022000147A1 CL 2022000147 A CL2022000147 A CL 2022000147A CL 2022000147 A CL2022000147 A CL 2022000147A CL 2022000147 A1 CL2022000147 A1 CL 2022000147A1
- Authority
- CL
- Chile
- Prior art keywords
- tmem16a
- modulators
- treatment
- pyridine derivatives
- respiratory conditions
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 102000003787 Anoctamin-1 Human genes 0.000 abstract 1
- 108090000160 Anoctamin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910607.9A GB201910607D0 (en) | 2019-07-24 | 2019-07-24 | Compounds |
| GBGB2005739.4A GB202005739D0 (en) | 2020-04-20 | 2020-04-20 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000147A1 true CL2022000147A1 (es) | 2022-10-07 |
Family
ID=71948615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000147A CL2022000147A1 (es) | 2019-07-24 | 2022-01-21 | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220235006A1 (https=) |
| EP (1) | EP4003516A1 (https=) |
| JP (1) | JP7583022B2 (https=) |
| KR (1) | KR20220063162A (https=) |
| CN (1) | CN114616226B (https=) |
| AU (1) | AU2020317036A1 (https=) |
| BR (1) | BR112022001164A2 (https=) |
| CA (1) | CA3145120A1 (https=) |
| CL (1) | CL2022000147A1 (https=) |
| CO (1) | CO2022002022A2 (https=) |
| CR (1) | CR20220072A (https=) |
| IL (1) | IL290035A (https=) |
| MX (1) | MX2022000841A (https=) |
| PE (1) | PE20221441A1 (https=) |
| PH (1) | PH12022550181A1 (https=) |
| WO (1) | WO2021014166A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
| WO2026038890A1 (ko) * | 2024-08-13 | 2026-02-19 | 광주과학기술원 | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176767A1 (en) | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| US11358947B2 (en) * | 2017-04-17 | 2022-06-14 | The Regents Of The University Of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
-
2020
- 2020-07-24 PE PE2022000119A patent/PE20221441A1/es unknown
- 2020-07-24 CA CA3145120A patent/CA3145120A1/en active Pending
- 2020-07-24 MX MX2022000841A patent/MX2022000841A/es unknown
- 2020-07-24 CR CR20220072A patent/CR20220072A/es unknown
- 2020-07-24 PH PH1/2022/550181A patent/PH12022550181A1/en unknown
- 2020-07-24 EP EP20751234.4A patent/EP4003516A1/en active Pending
- 2020-07-24 WO PCT/GB2020/051778 patent/WO2021014166A1/en not_active Ceased
- 2020-07-24 BR BR112022001164A patent/BR112022001164A2/pt not_active Application Discontinuation
- 2020-07-24 AU AU2020317036A patent/AU2020317036A1/en not_active Abandoned
- 2020-07-24 KR KR1020227006371A patent/KR20220063162A/ko not_active Ceased
- 2020-07-24 JP JP2022504089A patent/JP7583022B2/ja active Active
- 2020-07-24 CN CN202080053192.6A patent/CN114616226B/zh active Active
-
2022
- 2022-01-21 US US17/581,504 patent/US20220235006A1/en active Pending
- 2022-01-21 CL CL2022000147A patent/CL2022000147A1/es unknown
- 2022-01-23 IL IL290035A patent/IL290035A/en unknown
- 2022-02-24 CO CONC2022/0002022A patent/CO2022002022A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114616226A (zh) | 2022-06-10 |
| KR20220063162A (ko) | 2022-05-17 |
| CO2022002022A2 (es) | 2022-06-10 |
| CN114616226B (zh) | 2025-03-04 |
| CR20220072A (es) | 2022-06-29 |
| MX2022000841A (es) | 2022-06-08 |
| BR112022001164A2 (pt) | 2022-03-15 |
| JP7583022B2 (ja) | 2024-11-13 |
| PH12022550181A1 (en) | 2023-01-16 |
| JP2022541311A (ja) | 2022-09-22 |
| WO2021014166A1 (en) | 2021-01-28 |
| US20220235006A1 (en) | 2022-07-28 |
| IL290035A (en) | 2022-03-01 |
| CA3145120A1 (en) | 2021-01-28 |
| EP4003516A1 (en) | 2022-06-01 |
| AU2020317036A1 (en) | 2022-03-17 |
| PE20221441A1 (es) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020004249A2 (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CO2020010552A2 (es) | Compuestos | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| DE602004019198D1 (de) | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege | |
| MX392601B (es) | Análogos sintéticos de las ecteinascidinas y su uso como agentes antitumorales. | |
| CR7643A (es) | Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| ECSP15035530A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| SA521430330B1 (ar) | Eed و rc2 مشتقات آزولوبيريدين كبيرة الحلقة كمعدلات | |
| ATE534625T1 (de) | Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung | |
| UY28333A1 (es) | Inhibidores de caspasa y sus usos. | |
| MX2022011333A (es) | Compuestos moduladores de gpr52. | |
| UY39517A (es) | Inhibidores de la btk | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| CL2022000147A1 (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. |